Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Mystic River, Shutter Island author comes to campus Thursday
- Medical Informatics’ Rong Xu receives 2014 National Institute of Health Director’s New Innovator Award
- Kelvin Smith Library’s Jared Bendis presents technology news
- Tulane’s Daniel Bausch discussed Ebola threat at campus presentation
- Pre-med students: Learn about study abroad opportunities at Oct. 23 event